AZN Articles, AstraZeneca PLC - From 04/08/24

On Friday, the FDA approved Daiichi Sankyo Ltd’s (OTC:DSKYF) (OTC:DSNKY) and AstraZeneca Plc’s (NASDAQ:AZN) Enhertu...

As the weekend comes to a close, let’s take a look at the top stories that shaped the week. From the U.S. manufacturing sector hitting an 18-...

Friday, AstraZeneca Plc (NASDAQ:AZN) released high-level results of the ADRIATIC Phase 3 trial of Imfinzi monotherapy and Imfinzi plus Im...

AstraZeneca Plc’s (NASDAQ:AZN) Chief Executive Pascal Soriot says the company achieved a significant milestone by reaching a s...

Wednesday, Japan approved AstraZeneca Plc (NASDAQ:AZN) and Sanofi SA’s (NASDAQ:SNY) Beyfortus (nirsevimab), a long-a...

Thursday, Merck & Co Inc (NYSE:MRK) released topline data from the Phase 3 KEYLYNK-006 trial evaluating Keytruda (pembrolizumab) in c...

On Wednesday, GSK Plc (NYSE:GSK) announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month ...

H.C. Wainwright initiated coverage on Voyager Therapeutics Inc (NASDAQ:VYGR), noting a growing franchise of novel, highly-differenti...

Tuesday, AstraZeneca Plc (NASDAQ:AZN) agreed to acquire Fusion Pharmaceuticals Inc (NASDAQ:FUSN) for $21.00 per share in cash p...

Monday, AstraZeneca Plc (NASDAQ:PLC) released latest analysis of the results from the DUO-E Phase 3 trial of Imfinzi (durvaluma...